StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ELOXEloxx Pharmaceuticals, Inc.
stockpulse.co.kr
Nasdaq
$12.88▲ 1.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $52.0MShares out 4.0M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 3d agoAfter-hours26.10.22 08:33
    4Ownership#●●●

    Eloxx Pharmaceuticals, Inc.

    Insider Geno J. Germano of Eloxx Pharmaceuticals, Inc. reported a change in beneficial ownership of securities effective October 19, 2026. This filing was submitted via Form 4 to disclose the transaction.…more

    $12.88+1.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 3d agoPre-market26.10.22 08:33filed
    424B3Offering

    Eloxx Pharmaceuticals, Inc.

    Eloxx Pharmaceuticals has expanded its board from five to six members with the appointment of Geno J. Germano as a new director. Additionally, the company appointed Dr. T.R. Srinivas as Chief Medical Officer and finalized the design for its global Phase 2 clinical trial, EXPRESS, for the ADPKD treatment exaluren.…more

    $12.88+1.10%vs prev close
    View filingShare
  • 3d agoAfter-hours26.10.22 08:32
    3Ownership

    Eloxx Pharmaceuticals, Inc.

    Geno J. Germano of Eloxx Pharmaceuticals has filed a power of attorney to authorize designated individuals to execute and file SEC forms regarding securities holdings and transactions. This action establishes a legal framework for compliance with Section 16 reporting requirements.…more

    $12.88+1.10%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 4d agoRegular26.10.20 22:36
    #●●●#●●●#●●●

    Eloxx Pharmaceuticals Finalizes Design for Phase 2 ADPKD Trial

    Eloxx Pharmaceuticals has finalized the design for its Phase 2 global clinical trial targeting autosomal dominant polycystic kidney disease with 60 participants. The company expects to begin dosing in the third quarter of 2027, with topline results anticipated in the first half of 2029.…more

    $12.88+1.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.11Pre-market26.09.11 20:32

    ●●●●●●●● ●●●●● ●●●●●●

    Eloxx Pharmaceuticals has dosed the first two patients in its Phase 2b EXACT study for Exaluren, a treatment for nonsense mutation Alport syndrome. Topline results from the clinical trial are anticipated by mid-2027.…more

    $12.88+1.10%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →